Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (March 2018)
33 slides from Medical Developments International's investor presentation, Feb 26, 2018
Slide 1: Medical Developments International March 2018
For personal use only Medical Developments International March 2018
Slide 2: Disclaimer
Disclaimer For personal use only This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discu
Slide 3: Vision
Vision For personal use only Medical Developments International (MVP) is a leading Emergency Medicine Company. Our aim is to: 1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader globally. 2. Provide
Slide 4: Penthrox®
For personal use only Penthrox® 4
Slide 5: Penthrox is becoming mainstream in the UK and Ireland
Penthrox® Penthrox is becoming mainstream in the UK and Ireland For personal use only Everton’s James McCarthy suffered a double leg fracture in Everton’s premier league game against West Bromwich Shown on television show “24 Hours Source: Getty Images in ED” St George Hospital, UK - 2018 Source: Ge
Slide 6: Penthrox is becoming mainstream in the UK and Ireland
Penthrox® Penthrox is becoming mainstream in the UK and Ireland For personal use only Ireland centre Robbie Henshaw injured against Italy in the 2018 Six Nations Ireland’s Jordi Murphy is carried off the field during the first half of a match against New Zealand in Chicago, USA (Nov 2016) Source: Th
Slide 7: UK and Ireland update
Penthrox® UK and Ireland update For personal use only In market sales in the UK and Ireland grew 83% in H1FY18 vs H2FY17. There are 90 hospital formulary approvals. All 90 hospitals are ordering on a regular basis. Penthrox has been sold into 286 (up from 122 in October) Hospitals, clinics and ambul
Slide 8: France update
Penthrox® France update For personal use only Our partner is making excellent progress in France. In market sales in France are growing. In summary: • The target is 350 hospitals to approve Penthrox in France. • 250 formulary applications have already been submitted. • 115 formularies have approved
Slide 9: Regulatory approval for Penthrox in the rest of Europe
Penthrox® Regulatory approval for Penthrox in the rest of Europe For personal use only In addition to France, Belgium, UK, and Ireland we have 6 new European countries approved to sell Penthrox. We expect Regulatory Approvals for an additional 16 countries during 2018 – Bulgaria, Germany, Italy, Spa
Slide 10: Regulatory approval for Penthrox in the rest of World
Penthrox® Regulatory approval for Penthrox in the rest of World For personal use only 10
Slide 11: USA
Penthrox® USA For personal use only Work on getting Penthrox approved in the USA is progressing well. We are on track to submit our IND in the next few months. After discussions with the FDA we will request Penthrox be granted “fast track” status. We believe the aggressive negative bias against opio
Slide 12: A billion dollar opportunity in the USA
Penthrox® A billion dollar opportunity in the USA For personal use only 141 million admissions to the ER 33 million possible Penthrox cases pa.* each year in the USA.* Significant non narcotic bias Additional Future Indications for treatment of pain in the include: ER and elsewhere. Penthrox • Minor
Slide 13: Why Penthrox in the USA?
Penthrox® Why Penthrox in the USA? For personal use only Non-narcotic trauma relief, non- Penthrox can materially improve the throughput of addictive, safe.1 Not a restricted or patients7,8 in the ER because it enables better time to controlled medicine. analgesia and less medical care and observati
Slide 14: Potential cost analysis for USA
Penthrox® Potential cost analysis for USA Estimated costs of IV Opioid treatments Estimated costs of a Penthrox® For personal use only for acute pain treatment for acute pain* Drug Administration, Drug Staffing & Patient $15.75 Total Cost: Administration, Monitoring, $117 Total Cost: $25 $1,298 $563
Slide 15: Penthrox® clinical program for USA
Penthrox® Penthrox® clinical program for USA For personal use only 2017 2018 2019 2020 IND Toxicology: Additional Phase III to - 2 by 14 Day Repeat Dose Phase I Dose ranging support existing Phase III rat and dog studies Healthy Volunteer Study studies and data - General validation and assay studies
Slide 16: New manufacturing technology
Penthrox® New manufacturing technology For personal use only Construction of MVP’s new manufacturing facility was completed on time and on budget. The TGA issued the “Licence to Manufacture Pharmaceuticals” in February 2018. We expect GMP certificate and global regulatory approvals during H2FY18. Th
Slide 17: Future of MVP: New manufacturing technology
Future of MVP New manufacturing technology For personal use only Our ambition is to develop new patentable manufacturing technologies that will deliver cost saving, improved quality, consistency and safety standards for existing and new pharmaceutical products. We have successfully completed the Sta
Slide 18: Future of Penthrox® Clinical development program
Future of Penthrox® Clinical development program For personal use only Additional clinical trials and studies are planned for FY18 (and beyond) which will broaden the indications for use of Penthrox®. Our longer term ambition is to extend the use of Penthrox® into: • Acute Pain / Minor Surgical Proc
Slide 19: Outlook
Penthrox® Outlook For personal use only MVP’s ambition is to globalise Penthrox and in doing so make it the mainstream analgesic of choice around the world. That process has begun. Over the next 12 months+ we expect to: • obtain approval to sell Penthrox in 37 countries throughout Europe and in a nu
Slide 20: Respiratory and Medical Devices
For personal use only Respiratory and Medical Devices 20
Slide 21: Respiratory Division
Respiratory Division H1FY18 For personal use only Sales of Respiratory Devices in the USA grew 115%. We now have almost 13,000 pharmacies available to sell our product across the USA. Sales of Respiratory Devices in the UK and Europe grew 21%. Sales of Breath-A-Tech in Australia declined on a compar
Slide 22: Respiratory Devices: sold in more than 20 countries
Respiratory Devices Sold in more than 20 countries For personal use only Netherlands Switzerland Austria Germany Sweden UK Belgium Ireland Canada Greece Italy Cyprus USA Malta Gibralta Spain Korea Portugal Hong Kong Singapore Malaysia UAE KSA New Zealand Australia Kuwait 22
Slide 23: Respiratory Devices USA
Respiratory Devices USA For personal use only We have access to 13,000 pharmacies in the USA. We are core range for Walgreens, Walmart, Sam’s, Kmart and others. There are 67,000 pharmacies in the USA. The response to our product offering in the USA has been excellent. We are working on additional ph
Slide 24: Respiratory Devices Outlook
Respiratory Devices Outlook For personal use only MVP’s ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 20 countries. Over the next 12 months we expect to: • obtain additional partnership deals in the USA and
Slide 25: MVP Corporate
For personal use only MVP Corporate 25
Slide 26: H1 FY18 Penthrox sales
Penthrox® H1FY 18 For personal use only Sales of Penthrox to Ambulance in Australia remain strong. Sales of Penthrox to Hospitals and GP grew 38%. Sales of Penthrox to NZ Ambulance grew 305% as a result of all NZ Ambulances adopting Penthrox as first line sole analgesia. Delivered repeat order for U
Slide 27: Financial Summary
Financial Summary For personal use only During H1 MVP: • Delivered gross revenue of $8.0m down 3% • Sales of Respiratory Devices across the world fell 3% (mainly timing related). • Strong Gross Margins - increasing from 69% to 72%. • Moderate expense increases attributed to: - increased pharmacovigi
Slide 28: Financial Summary
Financial Summary For personal use only During H1FY18 MVP: • Declared a 2 cent fully franked dividend (DRP with a 5% discount again offered). • Drew down $3.5m of the $11m Debt Funding facility. • Invested: - $2.1m into USA regulatory program; - a further $1.2m into other clinical trials and Penthro
Slide 29: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3yr) Current Stock Price ▲ 0.110 (1.49%) 7.50 21 Feb, 10:18am Day High 7.500 Day Low 7.420 Open 7.420 Prev. Close 7.390 Avg. Volume 106,566 52 Wk. High 8.070 (12 Jan 2018) 52 Wk. Low 4.590 (1 Mar 2017) Mkt. Cap 443.23 (M
Slide 30: Intellectual Property
Intellectual Property For personal use only MVP is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. MVP has filed and is managing the following patents and trademarks: • 7 Penthrox Inhaler patents; • 5 Respiratory patents; • 1 manufact
Slide 31: MVP Corporate Overview
MVP Corporate Overview For personal use only David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing Director A Medical Co
Slide 32: Contact Details
Contact Details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com 32
Slide 33: For personal use only
For personal use only 0817 Medical Developments International
Medical Developments International — Investor Presentation (March 2018) on 6ix